The ACS Medicinal Chemistry Letters inspired articles in international science magazines. New Scientist, a UK based publication, contrasted the anti-cancer activity of NBS-1120 with Aspirin itself, highlighting the potential serious complications of long term dosing with Aspirin and referred to another scientific publication by Dr Kasfi that focused on the anticancer activity, mechanism of action and animal safety profile of NBS-1120 that appeared in Biochemical and Biophysical Research Communications [
link
].
The article in Science Daily reported that NBS-1120 demonstrated 250,000 times greater potency than aspirin alone in cultured cancer cells 72 hours after dosing. The article also highlighted that NBS-1120 activity was 15,000 times greater than existing NO-aspirins and 80-fold more than those that incorporate H2S, suggesting that the activity of NBS-1120 is greater than the sum of its parts.
The News Medical International article highlighted the activity of NBS-1120 in various cancer cell lines: The cancers controlled included colon, pancreatic, lung, prostate, breast, and leukemia. "The key components of this new compound are that it is very, very potent and yet it has minimal toxicity to the cells," said Associate Professor Khosrow Kashfi, the principal investigator.